Nebenwirkungen · Zejula
Zejula 100 mg hard capsules · Abschnitt 4.8 · PDF-Seite 11
HOS-136859 · Präparat HOS-097936
In NOVA, approximately 50% of patients experienced anaemia of any grade, and 25% experienced Grade 3/4 anaemia. The median time to onset of anaemia of any grade was 42 days, and 85 days for Grade 3/4 events. The median duration of anaemia of any grade was 63 days, and 8 days for Grade 3/4 events. Anaemia of any grade might persist during Zejula treatment. In the clinical programme, anaemia was managed with laboratory monitoring, dose modification (see section 4.2), and where appropriate with red blood cell transfusions. Discontinuation due to anaemia occurred in 1% of patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-10T15:04:00Z · SHA-256 6347b899b1ffe7609d7901f538d2dfbbead89a34d77901643cd1e86915c71a48 · Passage 2b3cec90d82e16b2dfeddaa281aff8da025ce2984fcdc8fc518b4726018d8e06 · Zeichen 11826–12410 im Abschnitt